124 related articles for article (PubMed ID: 35901589)
1. Central vs site outcome adjudication in the IRIS trial.
Forman R; Viscoli CM; Bath PM; Furie KL; Guarino P; Inzucchi SE; Young L; Kernan WN
J Stroke Cerebrovasc Dis; 2022 Sep; 31(9):106667. PubMed ID: 35901589
[TBL] [Abstract][Full Text] [Related]
2. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
Yaghi S; Furie KL; Viscoli CM; Kamel H; Gorman M; Dearborn J; Young LH; Inzucchi SE; Lovejoy AM; Kasner SE; Conwit R; Kernan WN;
Circulation; 2018 Jan; 137(5):455-463. PubMed ID: 29084736
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC
JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Kernan WN; Viscoli CM; Furie KL; Young LH; Inzucchi SE; Gorman M; Guarino PD; Lovejoy AM; Peduzzi PN; Conwit R; Brass LM; Schwartz GG; Adams HP; Berger L; Carolei A; Clark W; Coull B; Ford GA; Kleindorfer D; O'Leary JR; Parsons MW; Ringleb P; Sen S; Spence JD; Tanne D; Wang D; Winder TR;
N Engl J Med; 2016 Apr; 374(14):1321-31. PubMed ID: 26886418
[TBL] [Abstract][Full Text] [Related]
7. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Easton JD; Denison H; Evans SR; Knutsson M; Amarenco P; Albers GW; Ladenvall P; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC;
Int J Stroke; 2019 Dec; 14(9):908-914. PubMed ID: 31092152
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
[TBL] [Abstract][Full Text] [Related]
9. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
[TBL] [Abstract][Full Text] [Related]
10. Effect of pioglitazone on vascular events in post-stroke cognitive impairment: Post hoc analysis of the IRIS trial.
Schmidt K; Power MC; Ciarleglio A; Nadareishvili Z
Int J Stroke; 2024 Apr; 19(4):414-421. PubMed ID: 38148372
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
Inzucchi SE; Viscoli CM; Young LH; Furie KL; Gorman M; Lovejoy AM; Dagogo-Jack S; Ismail-Beigi F; Korytkowski MT; Pratley RE; Schwartz GG; Kernan WN;
Diabetes Care; 2016 Oct; 39(10):1684-92. PubMed ID: 27465265
[TBL] [Abstract][Full Text] [Related]
12. Adherence to study drug in a stroke prevention trial"?>.
Kiran A; Viscoli CM; Furie KL; Gorman M; Kernan WN
J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105048. PubMed ID: 32912514
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.
Furie KL; Viscoli CM; Gorman M; Ford GA; Young LH; Inzucchi SE; Guarino PD; Lovejoy AM; Conwit R; Tanne D; Kernan WN;
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):21-27. PubMed ID: 28939682
[TBL] [Abstract][Full Text] [Related]
14. Should we adjudicate outcomes in stroke trials? A systematic review.
Godolphin PJ; Bath PM; Montgomery AA
Int J Stroke; 2023 Feb; 18(2):154-162. PubMed ID: 35373672
[TBL] [Abstract][Full Text] [Related]
15. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Serebruany VL; Atar D
Thromb Haemost; 2012 Sep; 108(3):412-4. PubMed ID: 22836596
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
Viscoli CM; Inzucchi SE; Young LH; Insogna KL; Conwit R; Furie KL; Gorman M; Kelly MA; Lovejoy AM; Kernan WN;
J Clin Endocrinol Metab; 2017 Mar; 102(3):914-922. PubMed ID: 27935736
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
Liu J; Wang LN
Cochrane Database Syst Rev; 2015 Oct; (10):CD010693. PubMed ID: 26511368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
Spence JD; Viscoli C; Kernan WN; Young LH; Furie K; DeFronzo R; Abdul-Ghani M; Dandona P; Inzucchi SE
Diabetes Obes Metab; 2022 Jun; 24(6):1150-1158. PubMed ID: 35253334
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
Liu J; Wang LN
Cochrane Database Syst Rev; 2014 Jan; (1):CD010693. PubMed ID: 24399670
[TBL] [Abstract][Full Text] [Related]
20. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial.
Hata J; Arima H; Zoungas S; Fulcher G; Pollock C; Adams M; Watson J; Joshi R; Kengne AP; Ninomiya T; Anderson C; Woodward M; Patel A; Mancia G; Poulter N; MacMahon S; Chalmers J; Neal B;
PLoS One; 2013; 8(2):e55807. PubMed ID: 23390553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
